Back to discover
Disease

Diabetes Mellitus, Type 2

Late-stage therapeutic developmentExtensively researchedCooling momentum
MeSHDiabetes Mellitus, Type 2
423
Publications
24
Clinical trials
12
Related conditions
10
Related treatments
12
Associated genes
12
Related proteins
2026
Latest publication
Current focus
Glucagon-like 1 biologyInsulin biologyTherapeutic developmentInflammation & immunityMetabolic & lifestyle factors
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of BGM0504 Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone

Clinical trial2026-10-15Status changed to Active, not recruiting · ClinicalTrials.gov

Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Type 2 Diabetes Patients With Poor Blood Glucose Control After Diet and Exercise Intervention: a Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Study

Clinical trial2026-10-05Results posted · ClinicalTrials.gov

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

Clinical trial2026-09-08Status changed to Active, not recruiting · ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Noiiglutide Injection in Type 2 Diabetes Patients Who Received Metformin in Combination With or Without Another Oral Hypoglycemic Drug for Poor Blood Glucose Control -- a Phase III Clinical Trial of Multicenter, Randomized, Double-blind, Placebo Parallel Control

Clinical trial2026-08-25Status changed to Completed · ClinicalTrials.gov

A Phase 4, Open-Label, Single-Arm, 46-Week Study to Investigate the Safety and Efficacy With Tirzepatide in Adult Indian Participants With Either Type 2 Diabetes or Obesity

Clinical trial2026-08-21Status changed to Active, not recruiting · ClinicalTrials.gov

A Study Investigating Clinical Comparability of Two Formulations of Oral Semaglutide in Japanese Participants With Type 2 Diabetes

Clinical trial2026-08-13Status changed to Completed · ClinicalTrials.gov

ULTRA-T2D Study: Uric Acid Lowering Trial in Youth Onset T2D

Clinical trial2026-07-28Results posted · ClinicalTrials.gov

GLP-1 Receptor Agonists.

Research2026-04-01The New England journal of medicine

Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.

Research2026-01-14Lancet (London, England)

Market withdrawal: Bydureon (EMA)

Regulatory2026-01-01EMA

Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.

Research2026-01-01JAMA

The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.

Research2025-12-19International journal of molecular sciences

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Very High
Key developments
  • 6 clinical trials expected to report results, the earliest in Q1 2027.
  • Active recent publication activity, including 1 notable finding.
Upcoming Milestones
Research Highlights13View all 13
+7 more in the activity timeline below
Clinical Milestones13View all 13
Results posted 1
Results expected 5
Other updates 5
+5 more in the activity timeline below
Regulatory Updates6View
  • 2026-07-29Product authorisation ended — RepaglinideRepaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
  • 2026-05-04Product authorisation ended — TelmisartanHypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage.
  • 2026-04-30Product authorisation ended — TelmisartanHypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage.
  • 2026-01-01Product authorisation ended — ExenatideByetta is indicated for treatment of type-2 diabetes mellitus in combination with: metformin; sulphonylureas; thiazolidinediones; metformin and a sulphonylurea; metformin and a thiazolidinedione; in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. Byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and / or pioglitazone in adults who have not achieved adequate glycaemic control with these agents.
  • 2026-01-01Product authorisation ended — ExenatideBydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations). Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with: Metformin Sulphonylurea Thiazolidinedione Metformin and sulphonylurea Metformin and thiazolidinedione in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.
  • 2025-12-18Product authorisation ended — LixisenatideLyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
Activity timeline32

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Exenatideapproved

Product authorisation ended — Byetta is indicated for treatment of type-2 diabetes mellitus in combination with: metfo… (2026)

Repaglinideapproved

Product authorisation ended — Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes… (2026)

Telmisartanapproved

Product authorisation ended — Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Red… (2026)

Lixisenatideapproved

Product authorisation ended — Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve… (2025)

Dapagliflozinapproved

Generic approval — Type 2 diabetes mellitus Dapagliflozin Viatris is indicated in adults and children aged 1… (2023)

Semaglutideapproved

Original application approval — Adults Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical… (2022)

Sitagliptin hydrochlorideapproved

Generic approval — For adult patients with type 2 diabetes mellitus, Sitagliptin Accord is indicated to impr… (2022)

Tirzepatideapproved

Original application approval — Type 2 diabetes mellitus Mounjaro is indicated for the treatment of adults with insuffici… (2022)

Sitagliptin fumarateapproved

Generic approval — For adult patients with type 2 diabetes mellitus, Sitagliptin SUN is indicated to improve… (2021)

Showing the 10 strongest co-studied agents of 20 by shared papers — weaker co-mentions are not shown.

Clinical trials

15 sponsors · 5 new · 0 completed in the last 12 months (net +4)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)

Phase 3 · Active, not recruiting · EyePoint Pharmaceuticals, Inc.

Beta Cell Function in Type 2 Diabetes in Black Patients: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

Phase 4 · Active, not recruiting · MaryAnn Banerji

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

Phase 3 · Active, not recruiting · Pfizer

A 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)

Phase 4 · Active, not recruiting · Edward Wood, MD

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Phase 3 · Active, not recruiting · Eli Lilly and Company

A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema

Phase 2/3 · Active, not recruiting · EyeBiotech Ltd.
Recently completed

Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus

Phase 3 · Completed · Tanabe Pharma Corporation

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study

Phase 3 · Completed · Alimera Sciences

Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study

Phase 4 · Completed · Korea University Anam Hospital

A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control

Phase 3 · Completed · Boehringer Ingelheim

A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Trial of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite a Background Therapy of Pioglitazone Alone or in Combination With Metformin

Phase 3 · Completed · Boehringer Ingelheim

An Open-label, Randomized and Crossover Study to Assess the Effect of Co-administration of Vildagliptin and Voglibose on the Steady-state Pharmacokinetics / Pharmacodynamics in Japanese Patients With Type 2 Diabetes

Phase 4 · Completed · Novartis Pharmaceuticals

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

Product approvals and authorisations
2023emaGeneric approval — Dapagliflozin· Type 2 diabetes mellitus Dapagliflozin Viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. Heart failure Dapagliflozin Viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Chronic kidney disease Dapagliflozin Viatris is indicated in adults for the treatment of chronic kidney disease. source ↗
2022emaOriginal application approval — Tirzepatide· Type 2 diabetes mellitus Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1. Weight management Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obesity) or ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). source ↗
2022emaGeneric approval — Sitagliptin hydrochloride· For adult patients with type 2 diabetes mellitus, Sitagliptin Accord is indicated to improve glycaemic control: as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.- a peroxisome proliferator-activated receptor gamma (PPARy) agonist (i.e. a thiazolidinedione) when use of a PPARy agonist is appropriate and when diet and exercise plus the PPARy agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.- a PPARy agonist and metformin when use of a PPARy agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. Sitagliptin Accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control. source ↗
2022emaOriginal application approval — Semaglutide· Adults Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity), or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. For trial results with respect to cardiovascular risk reduction and populations studied, see section 5.1. Adolescents (≥12 years) Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with obesity* and body weight above 60 kg. Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose. *Obesity (BMI ≥95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1 in 4.1 of SmPC). Table 1 BMI cut-off points for obesity (≥95th percentile) by sex and age for paediatric patients aged 12 and older (CDC criteria) source ↗
2021emaGeneric approval — Sitagliptin fumarate· For adult patients with type 2 diabetes mellitus, Sitagliptin SUN is indicated to improve glycaemic control: as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.- a peroxisome proliferator-activated receptor gamma (PPAR?) agonist (i.e. a thiazolidinedione) when use of a PPAR? agonist is appropriate and when diet and exercise plus the PPAR? agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.- a PPAR? agonist and metformin when use of a PPAR? agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. Sitagliptin SUN is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control. source ↗
2020emaOriginal application approval — Semaglutide· Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in combination with other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. source ↗
2018emaOriginal application approval — Semaglutide· Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in addition to other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. source ↗
2015emaOriginal application approval — Dapagliflozin· Type 2 diabetes mellitus Edistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance. in addition to other medicinal products for the treatment of type 2 diabetes. For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. Heart failure Edistride is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney disease Edistride is indicated in adults for the treatment of chronic kidney disease. source ↗
Other regulatory activity
2026emaProduct authorisation ended — Repaglinide· Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals. source ↗
2026emaProduct authorisation ended — Telmisartan· Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage. source ↗
2026emaProduct authorisation ended — Telmisartan· Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage. source ↗
2026emaProduct authorisation ended — Exenatide· Byetta is indicated for treatment of type-2 diabetes mellitus in combination with: metformin; sulphonylureas; thiazolidinediones; metformin and a sulphonylurea; metformin and a thiazolidinedione; in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. Byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and / or pioglitazone in adults who have not achieved adequate glycaemic control with these agents. source ↗
2026emaProduct authorisation ended — Exenatide· Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations). Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with: Metformin Sulphonylurea Thiazolidinedione Metformin and sulphonylurea Metformin and thiazolidinedione in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. source ↗
2025emaProduct authorisation ended — Lixisenatide· Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

423 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
2015–2026
Most influential

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

Circulation · 2005 · 8,180 cites

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

The New England journal of medicine · 2015 · 8,145 cites

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

The New England journal of medicine · 2016 · 5,145 cites

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.

Journal of hepatology · 2020 · 3,285 cites

Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.

Lancet (London, England) · 2023 · 3,007 cites

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

European heart journal · 2020 · 2,718 cites
Recent publications

Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.

Hepatology (Baltimore, Md.) · 2026 · 45 cites

Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.

Lancet (London, England) · 2026 · 9 cites

The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.

The Journal of clinical investigation · 2026 · 6 cites

Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.

JAMA · 2026 · 6 cites

GLP-1 agonists and the gut microbiome: A bidirectional relationship.

British journal of clinical pharmacology · 2026 · 5 cites

GLP-1 and the cardiovascular system.

The Journal of clinical investigation · 2026 · 2 cites
Major themes8
  • Diabetes Mellitus, Type 2257
  • Glucagon-Like Peptide-1 Receptor Agonists91
  • Hypoglycemic Agents56
  • Cardiovascular Diseases47
  • Incretins29
  • Obesity29
  • Gastrointestinal Microbiome28
  • Insulin Resistance22
Leading journals6
  • Diabetes, obesity & metabolism22
  • International journal of molecular sciences22
  • Diabetes care20
  • Frontiers in endocrinology17
  • Diabetologia15
  • Cardiovascular diabetology14
Leading researchers8
  • Nauck MA13
  • Li Y12
  • Liu Y10
  • Wang X9
  • Buse JB8
  • Drucker DJ8
  • Holst JJ7
  • Inzucchi SE7
Affiliations (unnormalised)6
  • School of Medicine16
  • Brigham and Women's Hospital14
  • University of Copenhagen12
  • Steno Diabetes Center Copenhagen10
  • School of Pharmacy9
  • College of Medicine8

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

KCNJ110.86ABCC80.86GCK0.86PPARG0.86HNF1A0.78INSR0.78HNF1B0.77WFS10.76GLP1R0.76HNF4A0.76SLC2A20.74AKT20.72

Disease biology

12 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

ATP-sensitive inward rectifier potassium channel 11via KCNJ110.86ATP-binding cassette sub-family C member 8via ABCC80.86Peroxisome proliferator-activated receptor gammavia PPARG0.86Hepatocyte nuclear factor 1-alphavia HNF1A0.78Insulin receptorvia INSR0.78Glucagon-like peptide 1 receptorvia GLP1R0.76RAC-beta serine/threonine-protein kinasevia AKT20.72Gastric inhibitory polypeptide receptorvia GIPR0.68Sodium/glucose cotransporter 2via SLC5A20.64Dipeptidyl peptidase 4via DPP40.643-hydroxy-3-methylglutaryl-coenzyme A reductasevia HMGCR0.63Peroxisome proliferator-activated receptor alphavia PPARA0.63

Related conditions

12 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Obesity117Cardiovascular Diseases77Insulin Resistance48Weight Loss38Non-alcoholic Fatty Liver Disease31Inflammation24Metabolic Diseases22Metabolic Syndrome21Diabetes Mellitus, Type 120Heart Failure18Renal Insufficiency, Chronic17Diabetic Nephropathies14

Showing the 12 strongest of 82 by shared papers — weaker co-mentions are not shown.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Type 2 diabetes mellitus is a form of diabetes mellitus that is not insulin-dependent and is characterized early by insulin resistance and hyperinsulinemia. Over time it progresses to glucose intolerance, hyperglycemia, and overt diabetes. It is no longer considered a condition found only in adults, and patients seldom develop ketosis but often have obesity.

Causes

The supplied grounding supports a multifactorial basis rather than a single cause. Obesity-linked insulin resistance is implicated, and hypoadiponectinemia has been described as playing an important causal role in insulin resistance and type 2 diabetes. The gut microbiome is also linked to the disease in mechanistic reviews, suggesting contributions from host-microbe interactions.

Pathophysiology

The core biological feature is insulin resistance, with compensatory hyperinsulinemia early in the disease. The literature grounding also points to altered insulin secretion, disrupted energy and glucose metabolism, and changes in signaling pathways, with oxidative stress and gut microbiome-related effects implicated in disease biology. Adipokine signaling, including adiponectin and its receptors, is described as part of the antidiabetic regulatory network that is downregulated in obesity-linked insulin resistance.

Risk factors

Obesity is explicitly associated with type 2 diabetes in the supplied definition and reviews. Metabolic dysfunction and obesity-linked insulin resistance are supported risk contexts, and hypoadiponectinemia is described as contributing to disease development. The grounding also links the disease with diet and gut microbiome deviations, but does not support more specific risk estimates.

Current standard of care

Management is centered on lifestyle management and diabetes self-management education and support, with weight-loss efforts emphasized for patients with obesity. Drug therapy includes glucose-lowering medications such as metformin, GLP-1 receptor agonists, and SGLT2 inhibitors, with GLP-1 receptor agonists or SGLT2 inhibitors highlighted for patients with cardiovascular disease. The grounding also supports broader medication and surgical interventions for weight loss in appropriate patients, but does not provide regimen-level detail.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-06.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Identifiers
MeSHDiabetes Mellitus, Type 2
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.